DGAP-Adhoc: RHÃ?N-KLINIKUM AG: Intended increase of

RH�N-KLINIKUM AG / Key word(s): Miscellaneous 30.07.2013 12:15 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc-Notification pursuant to Section 15 (1) WpHG Intended increase of Asklepios' shareholding in RH�N-KLINIKUM AG to 10.1% of all shares prohibited by Federal Cartel Office By resolution dated 12 March 2013, the German Federal Cartel Office (Bundeskartellamt) had approved the increase of Asklepios Verwaltungsgesellschaft mbH's ('Asklepios') shareholding in RH�N-KLINIKUM AG to 10.1% subject to, amongst other conditions, the condition precedent of Asklepios selling the Harz clinic (Dr. Herbert-Nieper-Krankenhaus) and the medical service center (MVZ Harz) operated by Asklepios in the Goslar area to an independent hospital operator. For that purpose, Asklepios was also obligated under the resolution of the Federal Cartel Office to appoint a hold separate manager and a security trustee (Sicherungstreuhänder). On 29 July 2013, the Federal Cartel Office informed the Company that Asklepios will not fulfil the condition precedent. The mandates of the hold separate manager and the security trustee, which had been issued in the meantime, have been terminated by Asklepios. Hence, the conditions precedent can no longer be fulfilled. The Federal Cartel Office has declared that the intended increase of Asklepios' shareholding to 10.1% is now prohibited in accordance with the resolution of 12 March 2013. Due to the prohibition, the decision of the Federal Cartel Office of 12 March 2013 challenged by RH�N-KLINIKUM AG before the Higher Regional Court of Düsseldorf is obsolete (erledigt) in a legal sense. RH�N-KLINIKUM AG intends, however, to continue the clarification of the legal situation pursued with the appeal procedure by way of a continued appeal (Fortsetzungsfeststellungsbeschwerde). Thereby the Company intends, in view of a possible renewed filing for merger control clearance of the acquisition of a blocking minority by Asklepios, to have determined by the court that the merger control clearance of such acquisition is impermissible for a variety of reasons that, from the Company's point of view, were not taken into consideration in the Federal Cartel Office's decision of 12 March 2013. Contact: RH�N-KLINIKUM AG Dr. Kai G. Klinger Head of Investor Relations Schlossplatz 1 97616 Bad Neustadt a. d. Saale Tel: +49 (0) 9771 65-1318 Fax: +49 (0) 9771 99-1736 E-Mail: kai.klinger@rhoen-klinikum-ag.com Sascha Schiffler Head of Group Press and Public Relations Schlossplatz 1 97616 Bad Neustadt a. d. Saale Tel: +49 (0) 9771 65-1327 Fax: +49 (0) 9771 65-1820 E-Mail: kommunikation@rhoen-klinikum-ag.com 30.07.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: RH�N-KLINIKUM AG Schlossplatz 1 97616 Bad Neustadt a.d.Saale Germany Phone: +49 (0)9771 - 65-0 Fax: +49 (0)9771 - 97 467 E-mail: rka@rhoen-klinikum-ag.com Internet: www.rhoen-klinikum-ag.com ISIN: DE0007042301 WKN: 704230 Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------